|
Second-line treatment in a patient with refractory or recurrent disease
Hospital Sírio Libanês, São Paulo, Brazil
For patients who failed to respond or transiently responded to an initial intervention for metastatic colorectal cancer but are sufficiently fit to advance to second-line treatment, a survival benefit may be obtained from additional chemotherapy with standard agents (irinotecan, oxaliplatin, and 5-fluorouracil). The use of combination therapy is a preferred strategy to maximize exposure to as many effective agents as possible, and failure of first-line therapy should not be seen as a negative predictor of subsequent response.
| Commun Oncol 2007;4(suppl 2):12–15 | full text |  98 kb |